Immutep (ASX:IMM) said its first-in-human phase 1 trial showed a favorable safety profile of its lead drug candidate IMP761 being developed for various autoimmune diseases, according to a Tuesday filing with the Australian bourse.
Results from the first three of a five single-dose ascending study showed no adverse events, with pharmacokinetic and pharmacodynamic relationship report slated for release in the first half of next year, the filing said.
The company's shares were down nearly 3% in recent Tuesday trade.
Price (AUD): $0.33, Change: $-0.01, Percent Change: -2.94%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。